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Abstract
Intracranial classic (WHO grade II) and anaplastic (WHO grade III) ependymomas are among the most common
tumors in pediatric patients and have due to frequent recurrences and late relapses a relatively poor outcome. The
impact of histopathological grading on patient outcome is controversial and therefore, molecular prognostic and
predictive markers are needed to improve patient outcome. To date, the most promising candidate marker is
chromosome 1q gain, which has been associated in independent studies with adverse outcome. Furthermore, gene
expression and methylation profiles revealed distinct molecular subgroups in the supratentorial and posterior fossa
(PF) compartment and Laminin alpha-2 (LAMA2) and Neural Epidermal Growth Factor Like-2 (NELL2) were
suggested as surrogate markers for the two PF subgroups PF-EPN-A and PF-EPN-B. PF-EPN-A tumors were also
characterized by tenascin-C (TNC) expression and tenascin-C has been suggested as candidate gene on 9q, involved
in tumor progression. Therefore, we have analyzed the status of chromosome 1q, TNC, LAMA2, and NELL2
expression in a series of pediatric PF ependymomas in terms of their frequency, associations among themselves,
and clinical parameters, as well as their prognostic impact. We confirm the negative prognostic impact of 1q gain
and TNC expression and could classify PF ependymomas by these two markers into three molecular subgroups.
Tumors with combined 1q gain and TNC expression had the poorest, tumors without 1q gain and TNC expression had
a favorable and TNC positive 1q non-gained cases had an intermediate outcome. We found also differences in age and
tumor grade in the three subgroups and thus, provide evidence that PF pediatric ependymomas can be divided by
chromosome 1q status and TNC expression in three molecular subgroups with distinct clinico-pathological features.
These analyses require only few amounts of tumor tissue, are broadly available in the routine clinical neuropathological
setting and thus, could be used in further therapy trials to optimize treatment of ependymoma patients.
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Introduction
Ependymomas are neuroepithelial tumors, which arise
throughout the neuraxis and are usually associated with
the ventricular cavities or the spinal central canal. They
are considered to originate from radial glial stem cells [1]
and may occur at any age. Yet, distribution of localization,
genetic alterations, and outcome differ between adults and
children [2], necessitating different considerations regard-
ing biology and treatment approaches for the different age
groups. In the pediatric population ependymomas repre-
sent the fourth most common central nervous system
(CNS) tumor after low- and high-grade gliomas and me-
dulloblastomas [3]. In patients below 18 years, they
account for 5.5 % of all CNS tumors and this frequency
increases to 10.4 % in patients below 14 years with a peak
incidence in children between 1 and 4 years [3]. In con-
trast to adults where spinal localization predominates,
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ependymomas in children are located predominantly
intracranially, and most commonly in the posterior fossa
[2]. Outcome of pediatric patients with intracranial epen-
dymoma remains relatively poor with 5-year progression
free survival rates between 30 % and 69.1 % and 5 year
overall survival rates between 60 and 81 % in different age
groups and therapeutic trial cohorts [4–7]. Among clinical
factors the extent of resection is the most important prog-
nostic factor for patient outcome [8], but age below 3 years
and infratentorial location have been also suggested as un-
favorable prognostic markers [9, 10]. Histopathologically,
intracranial ependymomas comprise subependymoma
(WHO grade I), which is generally associated with a
favourable biological behavior, as well as classic (WHO
grade II) and anaplastic ependymomas (WHO grade III)
[11]. Data on the prognostic impact of tumor grade i.e.
classic versus anaplastic on patient outcome are controver-
sial. Whereas in some studies a better outcome of patients
with classic ependymomas was found [10, 12–14], this
could not be confirmed in other studies [15]. Thus, the bio-
logical behavior of ependymomas WHO grade II and III is
still poorly predictable, and there is a need for robust mo-
lecular prognostic and predictive markers to optimize treat-
ment strategies and improve patient outcome.
In the past years numerous markers including Ki67
proliferation, EGFR expression, Nestin, EZH2, human
telomerase reverse transcriptase hTERT/NCL, gain of
chromosome 9q, tenascin-C (TNC) and chromosome 1q
gain have been associated with patient outcome [16–21]
for review see [22]. Among these markers chromosome
1q gain seems to be the most promising marker, as its
negative prognostic impact could be shown in several
studies [17, 23–26]. Furthermore, recently two distinct
molecular ependymoma subgroups could be defined in
the infra- and supratentorial compartment, respectively
[27, 28]. The two supratentorial subgroups are charac-
terized by fusions of the RELA or YAP1 gene, respect-
ively [27, 29, 30] and patients with RELA fusion were
shown to have a worse prognosis in one study [27]. Pos-
terior fossa tumors could be classified into Group A
(EPN-PF-A) and B (EPN-PF-B) tumors [27, 28]. Group A
patients are younger, have frequently tumors with a bal-
anced genome and a worse prognosis compared to Group
B patients. Immunohistochemical expression of LAMA2
and NELL2 were proposed as markers for EPN-PFA and
EPN-PFB tumors, respectively and high tenascin-C (TNC)
expression was described in EPN-PFA tumors [28].
However, to date none of these markers is used for
therapy stratification. Therefore, the aim of this study
was to analyze in an ependymoma series, including
children and adolescents younger than 21 years, candidate
molecular markers, which require only few amounts of tu-
mors tissue and can be easily performed in a routine
clinical neuropathology setting and thus, might be




In the present study 52 children and adolescents
(≤21 years) operated on and/or treated for an intracra-
nial posterior fossa (PF) ependymoma at the Medical
University of Vienna between 1965 and 2014 were in-
cluded. Patients with subependymoma were excluded.
Clinical characteristics of the patients including treat-
ment are presented in Table 1.
Extent of tumor resection was determined by postop-
erative MRI within 72 hours of surgery from the early
1990s on. In earlier years the extent of tumor resection
was judged by the neurosurgeon only and confirmed by
CT when available and deemed necessary during the
Table 1 Clinical and biological characteristics of 52 pediatric
posterior fossa (PF) ependymomas















RTX and CTX 24 (46.1)
WHO grade
grade II 18 (34.6)









no gain 34 (65.4)
n.a. 8 (15.4)
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1980s. This study was approved by the Ethics Committee
of the Medical University of Vienna.
Histopathology
To confirm the diagnosis of ependymoma, tumor tissue
of all patients was reviewed without knowledge of
clinical information by A.A and C.H. Routine immuno-
histochemical stainings with antibodies against Olig2,
Vimentin, GFAP, EMA, NFP, NeuN, Synaptophysin,
CD34, and Ki67 were performed in all tumors. In 17 an-
aplastic tumors with structures reminiscent of multi-
layered rosettes, anti-LIN28A immunostaining (clone
A177, Cell Signaling, Danvers, USA; dilution 1:100) was
conducted to exclude an embryonal tumor with multi-
layered rosettes (ETMR). In 2 of the 52 patients only tis-
sue of the local relapse was available for analyses. In 4
patients tissue of the primary and the recurrent tumor
(3 local, 1 metastatic) was analysed. Histopathological
grading was performed according to the criteria of the
WHO classification of central nervous system tumors and
recent studies based on cellularity, frequency of mitotic
figures, and microvascular proliferations [11, 14, 24].
Immunohistochemistry
For immunohistochemical analyses 3 μm thick sections
of FFPE tumor tissue were cut. Antibodies against TNC
(clone E-9, Santa Cruz, Dallas, USA, dilution, 1:150),
LAMA2 (clone 2D4, Abnova, Taipei, Taiwan, dilution
1:500) and NELL2 (Abcam, Cambridge, United Kingdom,
dilution 1:5) were used. The protocol consisted of antigen
retrieval in a water bath at 98 °C using citrate buffer
(pH 9.0, 20 min for TNC and NELL2; pH 6.0, 20 min for
LAMA2). Detection of immunostaining was performed
using the Envision rabbit/mouse detection system (K5007,
Dako, Glostrup, Denmark) and diaminobenzidine as
chromogen. Lung squamous cell carcinoma, normal adult
pancreas and hippocampus were used as positive controls
for TNC, LAMA2 and NELL2, respectively. Despite dif-
ferent pretreatment protocols and antibody dilutions, no
reliable and reproducible results could be obtained for the
NELL2 antibody. Therefore, we refrained from evaluation
of the staining. According to previous studies the expres-
sion of TNC and LAMA2 was scored as positive or nega-
tive [18, 28, 31], labeling of vessel walls served as internal
positive control. TNC immunoreactivity was extracellular
and different expression patterns including predomin-
antly perivascular areas, the central or the border-
zone of the tumor tissue, as well as a mixture of
these patterns was observed. LAMA2 expression was
cytoplasmic.
Interphase fluorescent in situ hybridization (FISH)
Dual color FISH was carried out on FFPE sections as
previously described [32] using a commercially available
1q25 (spectrum green) and 1p36 (spectrum orange)
probe (Vysis® Abbott Laboratories, Abbott Park, IL,
USA). FISH slides were examined with an AxioImager
Z1 microscope (Carl Zeiss Microscopy, New York, USA)
using the ISIS software from MetaSystems (Altlussheim,
Germany). Signals were counted with x63 magnification
in at least 200 non-overlapping tumor cell nuclei in each
section. A signal ratio of 1q25/1p36 > 1 in a single nu-
cleus was considered as gain.
SNP arrays
In three patients SNP arrays were performed as previ-
ously published [33] to confirm the results of the FISH
analyses.
Statistical analyses
For statistical analysis, SPSS version 22.0 (SPSS Inc.,
Chicago, Illinois, USA) and SAS version 9.4 (SAS Insti-
tute Inc., Cary, NC, USA) were used. Associations be-
tween biological and clinical markers were assessed with
Spearman’s rank correlation coefficient. Overall survival
(OS) was defined from date of first operation until date
of death. Progression free survival (PFS) was defined
from date of first operation until date of disease progres-
sion, disease recurrence or death. Survival times of pa-
tients still alive or progression free at the end of the
observation period were considered censored with the
date of last contact. Survival probabilities were calcu-
lated with the product limit method of Kaplan and
Meier and corresponding confidence limits were calcu-
lated by applying the log-log transformation. The log-
rank test as well as univariate and multivariable Cox
proportional hazards regression models were used to as-
sess the effects of variables of interest on OS and PFS.
Whenever it was necessary to address numerical prob-
lems in the Cox model due to small sample sizes, the
Firth-correction was applied and Profile Likelihood
Confidence Limits were used [34]. All p-values are re-
sults of two-sided tests; values of p < 0.05 were consid-
ered statistically significant. As this study is exploratory
rather than confirmatory no adjustments for multiple
testing have been performed.
Results
Tumor grade, immunohistochemical and FISH analyses
Tumor characteristics including tumor grade and results
of immunohistochemical analyses are summarized in
Table 1. Briefly, 34.6 % of the tumors were classified as
grade II (Fig. 1a) and 65.4 % as grade III (Fig. 1b). TNC
immunoreactivity was extracellular (Fig. 1c) and different
expression patterns including predominantly perivascular
areas, the central or the border-zone of the tumor tissue,
as well as a mixture of these patterns was observed.
LAMA2 expression was cytoplasmic (Fig. 1d). TNC and
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Lama2 expression was detectable in 88.5 % and 53.8 % of
the tumors, respectively. In 4 patients, we analysed TNC
expression in both, the primary and recurrent tumor and
found an identical pattern (all positive).
FISH analysis revealed chromosome 1q25 gain (Fig. 1e)
in 10 tumors, 34 tumors had a balanced chromosome 1
(Fig. 1f). In 8 tumors (all operation dates before 1992) no
FISH signals were detectable despite repeated analyses.
The percentage of tumor cell nuclei with chromosome
1q25 gain (signal ratio 1q25/1p36 > 1 in a single cell)
ranged from 40.8 % to 83.5 % (median: 54.5 %) in gained
and from 0 % to 6.5 % (median 2 %) in balanced cases. To
corroborate the FISH results, we performed SNP arrays in
2 tumors with chromosome 1q25 gain (Fig. 1g) and in 1
tumor with balanced chromosome 1 (Fig. 1h). The FISH re-
sults could be confirmed in all three cases. All three tumors
with 1q25 gain had a gain of the whole chromosome arm
1q. Analysis of chromosome 1q25 in matched recurrences
Fig. 1 Histopathology and molecular markers in ependymoma. Classic expendymoma WHO grade II (a); anaplastic ependymoma WHO grade III
(b); ependymoma with TNC (c) and LAMA2 (d) expression; ependymoma with (e) and without (f) 1q25 gain (1q25 green fluorochrome, 1p36
red fluorochrome); g, h confirmation of iFSIH results by SNP arrays, Circos plots showing gain of chromosome arm 1q (g) and a balanced
copy-number profile (h)
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revealed in three tumors the same result as in the primary
lesion (2 cases with 1q25 gain, 1 balanced case). In one
local recurrence de novo 1q25 gain was detected.
Associations between clinical, pathological and molecular
markers
The results of association analyses between clinical,
pathological and molecular markers are provided in
Table 2. No significant associations were detected for
gender and extent of resection (data not shown). TNC
and LAMA2 expression were significantly associated
with younger patient age. TNC positive tumors were
more frequently anaplastic ependymomas, whereas this
association could not be found for LAMA2 positive tu-
mors. All tumors with chromosome 1q25 gain were ana-
plastic and TNC positive.
Survival analyses
At the last follow-up 29 (55.8 %) patients were alive. Six
patients were excluded from survival analyses because
five died perioperatively (operation dates before 1990),
and one died of another cause. The 5-year and 10-year
survival was 51.6 % (95 % confidence interval (CI) =
35.8–5.3) and 46 %. (95 % CI = 30.4–60.3). Median
follow-up was 174.7 months (range: 8.5–452.3 months).
Yet, before 1992 not all patients were treated with irradi-
ation, whereas after 1992, all patients primarily managed
at the Medical University of Vienna—independent of
age—were irradiated at least focally and received chemo-
therapy. Consequently, we found significant differences in
overall survival (OS) between patients operated before
and after 1992 (5-and 10- year OS 31.6 % (95 % CI =
12.9–52.2 %) and 26.3 % (95 % CI =9.6–46.8) versus
65.6 % (95 % CI =42.5–81.3) and 60.6 %, (95 % CI =37.5–
77.5) p < 0.001). Therefore, survival analyses were primar-
ily calculated for patients operated after 1992 (recent
cohort) and in a second step for all patients (entire co-
hort). Progression free survival (PFS) data were available
only for patients operated after 1992. 5-year and 10-year
PFS were 56.7 % (95 % CI =35.2–73.4) and 51.1 % (95 %
CI =29.4–69.1), respectively.
Results of survival analyses in the recent (1992–2014)
and the entire cohort (1965–2014) are presented in
Table 3. In brief, presence of chromosome 1q25 gain
had a significant negative impact on survival in the re-
cent (Fig. 2a) and approached significance in the entire
cohort (Fig. 2b). Presence of TNC expression did not
show a significant effect on OS, but approached signifi-
cance for PFS in the recent cohort (Fig. 2c), and had a
significant negative impact on OS in the entire cohort
(Fig. 2d). LAMA2 expression was not significantly asso-
ciated with survival. WHO grade nearly reached signifi-
cance in the recent cohort (Fig. 2e), but was not
significant in the entire cohort (Fig. 2f). Extent of resec-
tion did not significantly influence OS in the recent co-
hort, probably because only 3 patients did not have gross
total resection, but had a significant impact on PFS as well
as on OS in the entire cohort. No significant influence of
age and localization was detectable (data not shown).
In multivariable analyses including chromosome 1q25
status and TNC expression, only gain of chromosome
1q25 retained an independent prognostic marker for
PFS (Table 3). However, in view of the finding that TNC
expression had a significant impact in the entire cohort,
we defined three ependymoma groups using chromo-
some 1q25 status and TNC expression. We found sig-
nificant differences in PFS (Fig. 3b) and significance was
closely approached also in OS analyses (Fig. 3a, c). Pa-
tients harboring combined 1q25 gain and TNC expres-
sion had the poorest prognosis, followed by TNC
positive/1q25 non-gained tumors, whereas patients with
TNC negative/1q25 non-gained tumors had the best
outcome. We further analyzed clinical characteristics
and distribution of tumor grade in the three molecular
subgroups, in the entire cohort (1965–2014) (Table 4).
The median age of patients with TNC positive/1q25
non-gained tumors (group 2) was younger (2.14 years)
than in those with TNC positive/1q25 gained tumors
(group1) (4.5 years) and TNC negative/1q25 non-gained
tumors (group 3) (9.9 years). 4 of 5 patients with TNC
negative/1q25 non-gained tumors were male and had a
classic ependymoma (WHO grade II). All PF TNC posi-
tive/1q25 gained tumors were anaplastic (grade III), and
all TNC negative/1q25 non-gained tumors were classic
(grade II) ependymomas, whereas TNC positive/1q25
non-gained tumors comprised classic (n = 8) and anaplas-
tic (n = 21) ependymomas. In this subgroup no impact of
tumor grade on survival was detectable (p > 0.05).
Discussion
The aim of this study was to analyze the status of chromo-
some 1q, TNC, LAMA2, and NELL2 expression in a series
of pediatric PF ependymomas in terms of their frequency,
Table 2 Association of clinical and biological markers in
PF ependymomas, Spearman correlation coefficients






LAMA2 –.308* .056 .149
negative/positive
1q25 gain .265 .351* .194 –.158
absent/present
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associations among themselves and clinical parameters, as
well as their prognostic impact.
In intracranial ependymomas gain of chromosome 1q
is a frequent genomic aberration. It could be detected in
up to 24 % of all pediatric cases [13, 17, 23–26], whereas
it was found only in 8 % of adult patients in a metanaly-
sis [22]. In line with these previous findings we detected
1q gain in our series in 19.2 %. As previously described
gain of chromosome 1q was in our series associated with
anaplastic tumors (WHO grade III) [1, 17, 23, 26, 35–38].
In 2012, two studies confirmed the negative prognostic
impact of 1q gain on survival in pediatric patients treated
within the frame of therapeutic trials [24, 25]. Kilday et al.
described 1q gain as an independent prognostic marker
for PFS but not OS in three clinical trial cohorts including
ST and PF tumors. Godfraind et al. found a negative prog-
nostic impact on OS and PFS in uni- and multivariable
analyses in PF tumors. A recent study delineating molecu-
lar subgroups in the spinal, PF and ST compartment in a
mixed pediatric and adult population confirmed 1q as an
independent prognostic factor [27]. No prognostic impact
of 1q gain was found only in 2 studies [13, 37], one of
them could be due to low statistical power, because only 6
tumors with 1q gain were included [13]. We can confirm
in our retrospective study in an independent series of
intracranial ependymomas including children and adoles-
cents below 22 years the adverse prognostic impact of 1q
gain on OS and PFS, thus providing further evidence for
the prognostic significance of chromosome 1q status.
Interestingly, of the three patients with 1q gain still alive,
one female patient is surviving 23 years after diagnosis.
She was 4.4 years at diagnosis, had a gross total resection
and received an intense therapy including RTX and CTX.
This case highlights the possibility that even patients with
adverse molecular prognostic markers may be cured. This
is in line with a previous study describing 1q25 gain in the
CNS9904/RT group treated by radiotherapy as less pre-
dictive of a worse patient PFS or OS than in chemother-
apy trial cohorts [25]. The authors of this study suggested
that primary radiotherapy is an effective counteractive ad-
juvant measure despite the adverse effects of 1q25 gain.
In our series of 4 matched primary and recurrent tu-
mors 1 case showed a de novo 1q25 gain in the recurrent
tumor. This is in accordance with previous data showing
de novo 1q gain in single recurrences [23, 35, 39]. The
patient in our series with de novo 1q gain in a locally
recurrent tumor, which occurred 10 years after the pri-
mary tumor, had initially a TNC positive grade II epen-
dymoma, but is now after reoperation and 3 blocks of
PEI chemotherapy (VP16, Ifosfamid, Cisplatin), intraven-
tricular VP16 and DepoCyte, and focal radiotherapy in
complete remission 69 months after operation of the re-
lapse. This case emphasizes the occurrence of very late
relapses in ependymomas and thus, the importance of
Table 3 Survival analyses of clinical and biological markers in the recent and the entire cohort
Parameters Overall survival Progression free survival Overall survival
1992–2014 1992–2014 1965–2014
(n = 27) (n = 27) (n = 46)
HR (95 % CI) p-value HR (95 % CI) p-value HR (95 % CI) p-value
Univariate
Age (years) 0.957 (0.807; 1.135) 0.609 0.930 (0.800; 1.080) 0.324 0.956 (0.875; 1.046) 0.322
Extent of resection
GTR/non-GTR
1.416 (0.173; 11.57) 0.744 5.379 (1.068; 27.08) 0.042 2.876 (1.243; 6.657) 0.010
WHO grade
II/III
7.289 (0.911; 942.8) 0.065 2.421 (0.516; 11.36) 0.249 1.094 (0.448; 2.670) 0.844
TNC
positive/negative
3.739 (0.470; 483.4) 0.184 6.624 (0.841; 856.9) 0.079 9.583 (1.323; 1219) 0.031
LAMA2
positive/negative
1.800 (0.369; 8.776) 0.461 1.701 (0.466; 6.209) 0.416 1.141 (0.497; 2.619) 0.756
Chromosome 1q25
gain/no gain





1.872 (0.067; 52.31) 0.712 4.593 (0.505; 608.6) 0.348 3.807 (0.453; 496.7) 0.391
Chromosome 1q25
gain/no gain
4.409 (0.894; 21.74) 0.068 5.204 (1.369; 21.76) 0.024 2.025 (0.745; 5.307) 0.171
Extent of resection
GTR/non-GTR
2.662 (0.767; 9.235) 0.123 2.585 (0.908; 6.235) 0.057 2.135 (0.933; 4.464) 0.062
Hazard ratios (HR), 95 % confidence intervals (CI) and p-values are presented
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long-term follow-up, as well as the possibility to rescue
patients with recurrence, even if their tumor harbors
biologically unfavourable molecular features.
The extracellular matrix glycoprotein TNC is in the
CNS widely expressed during early development in
zones of proliferation, migration and morphogenesis
[40]. During further differentiation TNC is progressively
down-regulated, and in the adult CNS TNC expression
remains adjacent to areas of active neurogenesis such as
the hippocampus and the borders of the subventricular
zone (see refs [40, 41] and references therein). However,
it is actively re-expressed in the adult brain under
Fig. 2 Kaplan Meier overall survival curves for chromosome 1q status (a, b), TNC (c, d) and WHO grade (e, f) in the recent (1992–2014; a, c, e)
and the entire cohort (1965–2014; b, d, f)
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pathological conditions such as infection, inflammation,
wound healing or tumorigenesis [40]. It could be shown
that gliomas grade II and III with pronounced perivascu-
lar TNC staining had a shorter disease- free time and in
vitro TNC blocking antibodies inhibited proliferation
and migration in glioblastoma [42]. Furthermore, target-
ing TNC by radiolabeled antibodies and RNAi have
shown promising results in patients with malignant
gliomas (for review see [43]). In ependymomas TNC
expression has been associated with anaplastic tumors
[31, 44–46]. A significant impact of TNC expression on
PFS could be shown in two studies [31, 46]. TNC has
been described as candidate gene for ependymoma pro-
gression in posterior fossa tumors with gain of 9pter
[18]. TNC expression was found in 94 % of posterior
fossa Group A tumors and only in 11 % of posterior
fossa Group B tumors [28] and thus, seems to be a
marker for the majority of PF Group A ependymomas.
We found TNC expression in almost 90 % of the tu-
mors. In line with previous reports it was significantly
associated with anaplastic tumors [31, 44–46]. Similar to
the report by Modena we found an association with
younger patient age [47]. We detected a significant im-
pact of TNC expression on OS in our entire cohort
(1965–2014), and a tendency towards significance on
PFS in the recent cohort. A possible explanation for the
lack of significance in the recent cohort could be that
the biological impact of TNC is blurred by improved ad-
juvant treatment.
LAMA2 (Laminin alpha-2) expression has been sug-
gested as a surrogate marker for PF Group A ependymo-
mas [28]. We found LAMA2 expression in approximately
50 % of all PF tumors. In a previously analyzed cohort of
PF ependymomas LAMA2 was expressed in 67 % of the
tumors in patients ≤ 21 years, thus in a similar percentage,
however 10 % of these patients expressed also NELL2
[28]. In our series, no significant association between
LAMA2 and TNC was detectable and we could not find a
prognostic impact of LAMA2. NELL2 (Neural Epidermal
Growth Factor Like-2), which has been suggested as
surrogate marker for PF Group B ependymomas [28], did
not show reproducible results in our hands, thus this
marker does not seem to be a useful, robust marker for
routine clinical use.
As we detected a prognostic impact of chromosome
1q status and TNC expression we combined these two
markers and defined 3 molecular subgroups. Actually,
we found survival differences in OS and PFS. Patients
whose tumors harbored combined 1q gain and TNC ex-
pression (group 1) had the poorest prognosis, whereas
no 1q gain and lack of TNC expression (group 3) was
associated with a favorable outcome. Group 1 and 2
probably correspond to the previously described PF-
EPN-A and group 3 to the PF-EPN-B subgroup [27, 28].
Group 3 tumors might represent a very favorable mo-
lecular group and patients with such tumors might be
treated less aggressively, thereby reducing long-term side
effects. Indeed, one 11-year-old male patient with a
tumor without 1q25 gain and TNC expression, who had
a gross total resection did not receive any adjuvant treat-
ment and is alive 35 years after operation. We further
analyzed whether these three molecular subgroups are
Fig. 3 Survival probabilities for three molecular subgroups: OS (a) and PFS (b) in the recent cohort (1992–2014) and (c) OS in the entire
cohort (1965–2014)
Table 4 Clinical characteristics and distribution of WHO grade
in three different ependymoma groups defined by TNC
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associated with distinct clinico-pathological features
(Table 4). Actually, the median age of patients with group
2 tumors was younger than that of patients with group 1
tumors, and median age of patients with group 3 tumors
was highest. There were also differences regarding the
tumor grade, whereas all group 1 tumors were anaplastic
(WHO grade III), all group 3 tumors were classic (WHO
grade II) and we found a preponderance of male patients
in group 3 tumors. This further provides evidence that the
three groups represent biologically distinct subgroups, and
that PF-EPN-A tumors can be split into 2 subgroups with
different outcome and clinico-pathological features.
Conclusions
In summary, we confirm in an independent series of
pediatric ependymoma patients the negative prognostic
impact of chromosome 1q25 gain and TNC expression
in PF ependymomas and provide evidence that PF epen-
dymomas can be split into three different molecular sub-
groups with distinct clinico-pathological features and
outcome, which could be used in future trials to
optimize treatment of ependymoma patients.
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